Halozyme Names Alison A. Armour as Senior Vice President of Research and Development
May 06, 2019 at 05:30 pm IST
Share
Halozyme Therapeutics, Inc. announced the appointment of Alison A. Armour, M.B. Ch.B., B.Sc., M.Sc., M.D., FRCR, FRCP, as senior vice president, research and development, effective immediately. In this role, she will report to Dr. Helen Torley, president and chief executive officer. Dr. Armour will lead Halozyme's research, clinical development, regulatory, safety and pharmacovigilance efforts. Alison's immediate focus will be the PEGPH20 regulatory submissions for pancreas cancer in the event of positive data. She will also play a key role in shaping the PEGPH20 new indication development strategy and expanding oncology portfolio. Dr. Armour joins Halozyme from Endocyte, where she served as Chief Medical Officer.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Companyâs ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.